Alirocumab (anti-PCSK9)

Product Name： Alirocumab  biosimilar

CAS No.:    1245916-14-6                             

Formula:      C₆₄₇₂H₉₉₉₆N₁₇₃₆O₂₀₃₂S₄₂                

Molecular Weight：  146 kDa                  

Type:      Whole antibody                   

Target：  PCSK9
Antibody Form:  Purified immunoglobulin
Physical Form:  Solution
Storage:  -70±15℃ for long-term storage, 2-8℃ for short-term storage, away from light.

Description

Alirocumab biosimilar is a human monoclonal antibody (IgG1 isotype) that targets proprotein convertase subtilisin kexin type 9 (PCSK9), is a PCSK9 inhibitor produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Alirocumab biosimilar consists of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. A single Nlinked glycosylation site is located in each heavy chain within the CH2 domain of the Fc constant region of the molecule. The variable domains of the heavy and light chains combine to form the PCSK9 binding site within the antibody. Alirocumab biosimilar has an approximate molecular weight of 146 kDa.

Biological Activity
Alirocumab (anti-PCSK9) works by inhibiting the PCSK9 protein, which binds to the low-density lipoprotein receptor (LDLR) and causes receptor degradation, removing less LDL cholesterol from the circulation.

For research use only. Not for use in humans